AMGEN and Janssen Biotech Inc. announced a collaboration to evaluate the combination of Amgen’s Kyprolis (carfilzomib) and Janssen’s Darzalex (daratumumab) in multiple clinical studies in patients with multiple myeloma. Under the agreement, the companies may elect to supply drug only or supply drug and share development costs on a study-by-study basis.The first study initiated as...
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
